Regulatory Affairs Committee

The Regulatory Affairs Committee educates members on the worldwide regulatory environment and interacts directly with the FDA regarding gene and cell therapy. The committee also provides Society representation to entities developing gene and cell therapy standards.
Full NamePositionOrganizationTerm StartTerm End
Kimberly Benton, PhDChairDark Horse Consulting Group6/1/20265/31/202763591
Aron SteinMemberIntellia Therapeutics6/1/20255/31/202831709
Sai Prathyusha BhamidipatiMemberModerna6/1/20255/31/202849704
Lesbeth Caridad RodriguezMemberBayer6/1/20255/31/202864129
Jessica Chery, PhDMemberFood and Drug Administration6/1/20235/31/202933575
John JamesonMemberAskBio6/1/20255/31/202863074
Rachel Ruckdeschel Smith, PhDMemberAtsena Therapeutics6/1/20255/31/202853342
Elizabeth MellenMemberStoke Therapeutics6/1/20255/31/202840511
Karen Nichols, Esq.MemberNichols Consulting Enterprises LLC6/1/20265/31/202949459
Shana H. Thomas, PhDMemberKite Pharma, a Gilead Company6/1/20245/31/202761110
John Noh, PharmDMemberVironexis Biotherapeutics, Inc6/1/20265/31/2029100422
Dunni Odumosu, MSMemberBridgeBio6/1/20245/31/202741938
Dylan BechtleMemberJohnson & Johnson6/1/20255/31/202838418
Kiley J. Keelin, M.S.MemberKey Strategy and Regulatory Consulting6/1/20265/31/202935301
Andrew LiermannStaff LiaisonASGCT6/1/20245/31/204589829